These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15206026)

  • 1. Bartter syndrome: benefits and side effects of long-term treatment.
    Vaisbich MH; Fujimura MD; Koch VH
    Pediatr Nephrol; 2004 Aug; 19(8):858-63. PubMed ID: 15206026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.
    Reinalter SC; Jeck N; Brochhausen C; Watzer B; Nüsing RM; Seyberth HW; Kömhoff M
    Kidney Int; 2002 Jul; 62(1):253-60. PubMed ID: 12081585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Bartter syndrome. Unsolved issue.
    Nascimento CL; Garcia CL; Schvartsman BG; Vaisbich MH
    J Pediatr (Rio J); 2014; 90(5):512-7. PubMed ID: 24878005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful management of an extreme example of neonatal hyperprostaglandin-E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib.
    Haas NA; Nossal R; Schneider CH; Lewin MA; Ocker V; Holder M; Uhlemann F
    Pediatr Crit Care Med; 2003 Apr; 4(2):249-51. PubMed ID: 12749662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal Bartter syndrome--use of indomethacin in the newborn period and prevention of growth failure.
    Mackie FE; Hodson EM; Roy LP; Knight JF
    Pediatr Nephrol; 1996 Dec; 10(6):756-8. PubMed ID: 8971899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive acetazolamide therapy for the treatment of Bartter syndrome.
    Mazaheri M; Assadi F; Sadeghi-Bojd S
    Int Urol Nephrol; 2020 Jan; 52(1):121-128. PubMed ID: 31820361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment options for Bartter's syndrome.
    Kleta R; Basoglu C; Kuwertz-Bröking E
    N Engl J Med; 2000 Aug; 343(9):661-2. PubMed ID: 10979805
    [No Abstract]   [Full Text] [Related]  

  • 8. Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome.
    Proesmans W; Massa G; Vanderschueren-Lodeweyckx M
    Pediatr Nephrol; 1988 Apr; 2(2):205-9. PubMed ID: 3153013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bartter's syndrome: 10 cases in childhood. Results of long-term indomethacin therapy.
    Dillon MJ; Shah V; Mitchell MD
    Q J Med; 1979 Jul; 48(191):429-46. PubMed ID: 120550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Furosemide-induced tubular dysfunction responding to prostaglandin synthesis inhibitor therapy in a child with nephrotic syndrome.
    Varma TH; Sharma A; Santhiya S; Dawman L; Tiewsoh K
    CEN Case Rep; 2018 Nov; 7(2):195-197. PubMed ID: 29568987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bartter's syndrome: the long term effects of indomethacin on growth (author's transl)].
    Floret D; David M; Roux A; Hage GN; Teyssier G
    Nouv Presse Med; 1979 Jan; 8(1):17-21. PubMed ID: 122007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-pubertal growth in the hyperprostaglandin E syndrome.
    Seidel C; Reinalter S; Seyberth HW; Schärer K
    Pediatr Nephrol; 1995 Dec; 9(6):723-8. PubMed ID: 8747113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance induction to rofecoxib in a patient with Bartter's syndrome.
    Nucera E; Schiavino D; Pollastrini E; Manna R; Di Lillo M; Buonomo A; Roncallo C; Patriarca G
    Allergy; 2004 Jul; 59(7):788-9. PubMed ID: 15180770
    [No Abstract]   [Full Text] [Related]  

  • 14. Bartter syndrome in a neonate: early treatment with indomethacin.
    Mourani CC; Sanjad SA; Akatcherian CY
    Pediatr Nephrol; 2000 Feb; 14(2):143-5. PubMed ID: 10684365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome: therapeutic use of the cyclooxygenase-2 inhibitor nimesulide.
    Nüsing RM; Reinalter SC; Peters M; Kömhoff M; Seyberth HW
    Clin Pharmacol Ther; 2001 Oct; 70(4):384-90. PubMed ID: 11673754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polyhydramnios, prematurity, dystrophy, polyuria, constipation, nephrocalcinosis and renal tumor: presentation of a classic tubulopathy].
    Schnakenburg Cv; Frankenschmidt A; Neumann J; Häffner K; Jeck N; Pohl M
    Klin Padiatr; 2008; 220(1):24-5. PubMed ID: 18172829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classic Bartter syndrome: a rare cause of failure to thrive in a child.
    Vieira H; Mendes L; Mendes P; da Silva JE
    BMJ Case Rep; 2012 Jun; 2012():. PubMed ID: 22744244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bartter syndrome: a new therapeutic approach].
    Mendonça M; Pinheiro A; Castro I
    Acta Med Port; 2011 Dec; 24 Suppl 3():671-4. PubMed ID: 22856410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibitors and hypercoagulability.
    Farkouh ME
    Clin Adv Hematol Oncol; 2005 Jan; 3(1):35-6. PubMed ID: 16166966
    [No Abstract]   [Full Text] [Related]  

  • 20. Patient empowerment: rofecoxib revisited.
    Tannenbaum H
    J Rheumatol; 2006 Jun; 33(6):1033-5. PubMed ID: 16755647
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.